Letter by Rassi et al regarding article, "β-blocker therapy and mortality of patients with chagas cardiomyopathy: A subanalysis of the REMADHE prospective trial"

Circulation: Heart Failure

Volumn 3, Issue 3, 2010, Pages

  Rassi Jr , Anis ^a  

^a Anis Rassi Hospital   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; SPIRONOLACTONE;

CHAGAS DISEASE; CLINICAL TRIAL; DEFIBRILLATOR; HEART FAILURE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; LETTER; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; MORTALITY; NOTE;

ADRENERGIC BETA-ANTAGONISTS; CHAGAS CARDIOMYOPATHY; HEART FAILURE; HUMANS; TREATMENT OUTCOME;

EID: 77954733531     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.110.940999     Document Type: Letter

References (2)

1. Issa VS, Amaral AF, Cruz FD, Ferreira SM, Guimarães GV, Chizzola PR, Souza GE, Bacal F, Bocchi EA. Beta-blocker therapy and mortality of patients with Chagas cardiomyopathy: a subanalysis of the REMADHE prospective trial. Circ Heart Fail. 2010;3:82-88.
2. Scanavacca MI, Brito FS, Maia I, Hachul D, Gizzi J, Lorga A, Rassi A Jr, Filho MM, Mateos JC, D'Avila A, Sosa E. Guidelines for the evaluation and treatment of patients with cardiac arrhythmias. Arq Bras Cardiol. 2002;79(suppl 5):1-50.